Abstrakt

Heart failure (HF) affects an estimated 64 million individuals worldwide and remains a leading cause of hospitalization and mortality, with a 5-year survival rate of approximately 58%. Despite advances in therapy, HF-related admissions—particularly among patients over 65 years—continue to rise due to population aging and increasing comorbidities.
Haemodynamic management guided by left-ventricular filling pressure (LVFP) has been shown to improve quality of life, reduce HF hospitalizations, and enhance survival. However, currently available LVFP monitoring systems are invasive, costly, and require lifelong antithrombotic therapy. Seerlinq HeartCore is a non-invasive, CE-certified (MDR Class IIb) system for remote LVFP monitoring based on photoplethysmography (PPG) recorded from patients while calmly standing and in recumbent position. This change of position provokes hemodynamic response due to redistribution of patient’s circulating volume. The nature of this hemodynamic response differs between a heart with normal filling pressure and one with elevated filling pressure. These changes are then reflected in blood volume changes in the microvascular bed of tissue and can be measured by PPG sensors. Given the established benefits of LVFP-guided management and the limitations of invasive systems, the STOP-DHF (Strategy TO Prevent Decompensated Heart Failure) trial was designed to evaluate the clinical utility of Seerlinq-guided therapy as a non-invasive alternative. To evaluate the effectiveness of the Seerlinq system in a real-world heart failure patient population.

Klíčová slova

heart failure (HF), left‑ventricular filling pressure (LVFP), hemodynamic monitoring, photoplethysmography (PPG), Seerlinq HeartCore, non‑invasive monitoring, postural hemodynamic response, personalized medicine, STOP‑DHF trial, cardiovascular risk